natgillin/translations-raw huggingface dataset:
1 mg filmovertrukne tabletter på 5 mm x 10 mm: Lyseblå, kapselformede, bikonvekse tabletter præget ”Pfizer” på den ene side og ”CHX 1.0” på den anden side. 
1 mg film-coated tablets of 5mm x 10mm: Light blue, capsular-shaped, biconvex tablets debossed with “Pfizer” on one side and “CHX 1.0” on the other side.
N=1017 n (%) 
Bupropion N=1017 n (%)
N=989 n (%) 
Bupropion N=989 n (%)
CHAMPIX 0,5 mg CHAMPIX 1 mg Filmovertrukne tabletter Vareniclin 
CHAMPIX 0.5 mg CHAMPIX 1 mg Film-coated tablets Varenicline
Efter markedsføringen er der rapporteret om en øget berusende virkning af alkohol hos patienter, der blev behandlet med vareniclin, men der er ikke etableret en årsagssammenhæng. 
There have been post marketing reports of increased intoxicating effects of alcohol in patients treated with varenicline.
Lægemidlet er receptpligtigt. 
This medicine has been prescribed for you only.
CA* uge 13-52 
CA* wk 21-52
Denne indlægsseddel blev senest ændret <{måned ÅÅÅÅ}.> 
This leaflet was last revised in
CHAMPIX kan virke dæmpende på Deres trang til at ryge, samtidig med at den lindrer de abstinenssymptomer, der opstår, når De holder op med at ryge. 
CHAMPIX can help to relieve the craving and withdrawal symptoms associated with stopping smoking.
Ved at hindre nicotin i at virke på α4β2-receptorerne (antagonist virkning) nedsætter det samtidig belønningsoplevelsen og rygningens selvforstærkende mekanisme. 
The efficacy of CHAMPIX in smoking cessation is a result of varenicline's partial agonist activity at the α4β2 nicotinic receptor where its binding produces an effect sufficient to alleviate symptoms of craving and withdrawal (agonist activity), while simultaneously resulting in a reduction of the rewarding and reinforcing effects of smoking by preventing nicotine binding to α4β2 receptors (antagonist activity).
BILAG I 
Panic b
MACE, n (%) 
During treatment MACE, n (%)
For ældre patienter med nedsat nyrefunktion se pkt. 
For elderly patients with reduced renal function please refer to section 4.2.
De vigtigste sekundære endepunkter var CA for uge 13 til og med uge 52. 
A key secondary endpoint was the continuous abstinence (CA) rate for week 13 through week 52.
Hver 0,5 mg filmovertrukken tablet indeholder 0,5 mg vareniclin (som tartrat). 
- Each 0.5 mg film-coated tablet contains 0.5 mg of varenicline (as tartrate).
- CHAMPIX 1 mg filmovertrukne tabletter er lyseblå, filmovertrukne, kapselformede tabletter, mærket ”Pfizer” på den ene side og ”CHX 1.0” på den anden. 
CHAMPIX 1 mg film-coated tablets are light blue film-coated, modified capsular shaped tablets, marked “Pfizer” and “CHX 1.0”
MINDSTEKRAV TIL MÆRKNING PÅ BLISTER ELLER TRIP 
ANNEX III LABELLING AND PACKAGE LEAFLET
HDPE beholder med polypropylen børnesikret lukning og aluminiumsfolie/polyethylen forsegling, indeholdende 56 x 0,5 mg filmovertrukne tabletter. 
High-density polyethylene (HDPE) bottle with polypropylene child resistant closure and an aluminium foil/polyethylene induction seal containing 56 x 0.5 mg film-coated tablets Not all pack sizes may be marketed.
Suicidaladfærd og/eller -tanker Suicidaladfærd Suicidaltanker 
Number assessed Suicidal behaviour and/or ideation Suicidal behaviour Suicidal ideation
- Vedligeholdelsespakninger, der indeholder 2 eller 4 gennemsigtige blisterkort hver med 14 eller 2 gennemsigtige blisterkort med 28 x CHAMPIX 0,5 mg filmovertrukne tabletter i en kortpakning. 
Follow-on (maintenance) packs containing 2 or 4 clear blisters of 14 or 2 clear blisters of 28 x CHAMPIX 0.5 mg film-coated tablets in card packaging.
Samtidig behandling med cimetidin og vareniclin bør undgås hos patienter med svært nedsat nyrefunktion. 
In patients with severe renal impairment, the concomitant use of cimetidine and varenicline should be avoided.
Pollakisuri, nykturi 
Pollakiuria, nocturia
Allergiske reaktioner 
Adverse Drug Reactions
Karton indeholdende 1 blisterkort med 11 x 0,5 mg vareniclin filmovertrukne tabletter og 1 blisterkort med 14 x 1 mg vareniclin filmovertrukne tabletter 
Carton pack with 1 blister pack of 11 x 0.5 mg varenicline film-coated tablets and 1 blister pack of 14 x 1 mg varenicline film-coated tablets
Vareniclin kan fjernes ved dialyse, hvilket blev vist hos patienter med nyresygdom i sidste stadie (se pkt. 
Varenicline has been shown to be dialyzed in patients with end stage renal disease (see section 5.2), however, there is no experience in dialysis following overdose.
Her virker det som en partiel agonist, det vil sige en forbindelse, der både viser agonist-virkning, men som er mindre virkningsfuld end nicotin, og som har antagonist-virkning ved tilstedeværelse af nicotin. 
Varenicline binds with high affinity and selectivity at the α4β2 neuronal nicotinic acetylcholine receptors, where it acts as a partial agonist - a compound that has both agonist activity, with lower intrinsic efficacy than nicotine, and antagonist activities in the presence of nicotine.
Oddsratio 
Odds ratio
Suicidal adfærd Suicidaltanker Gennemført selvmord Sammensat endepunkt for NPS AE af svær grad, n 
Completed suicideb Composite NPS AE Endpoint of severe intensity n (%)
HDPE beholder med polypropylen børnesikret lukning og aluminiumsfolie/polyethylen forsegling, indeholdende 56 x 1 mg filmovertrukne tabletter. 
High-density polyethylene (HDPE) bottle with polypropylene child resistant closure and an aluminium foil / polyethylene induction seal containing 56 x 1 mg film-coated tablets Not all pack sizes may be marketed.
- Svampeinfektion, virusinfektion - Panikanfald, vanskelighed ved at tænke, rastløshed, humørsvingninger, depression, angst, 
Uncommon: may affect up to 1 in 100 people o Fungal infection, viral infection o Feeling of panic, difficulty thinking, restlessness, mood swings, depression, anxiety,
Hver 1 mg filmovertrukken tablet indeholder 1 mg vareniclin (som tartrat). 
- Each 1 mg film-coated tablet contains 1 mg of varenicline (as tartrate).
- Vedligeholdelsespakninger, der indeholder 2, 4, 8 eller 10 gennemsigtige blisterkort hver med 14 x 1 mg filmovertrukne tabletter i en karton. 
Follow-on (maintenance) packs containing 2, 4, 8, or 10 clear blisters of 14 x CHAMPIX 1 mg film-coated tablets in a carton.
Tidligere psykiske forstyrrelser 
History of psychiatric disorders
Startpakninger: 
Treatment initiation packs:
1,74 (1,43, 2,10), P<0,0001 1,62 (1,32, 1,99), P<0,0001 
1.74 (1.43, 2.10), P<0.0001
Hver tablet indeholder 0,5 mg eller 1 mg vareniclin (som tartrat). 
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 0.5 mg or 1 mg varenicline (as tartrate).
Det skal De vide, før De begynder at tage CHAMPIX Sådan skal De tage CHAMPIX Bivirkninger 
What you need to know before you take CHAMPIX 3.
I disse studier, der forløb over 52 uger, fik patienterne behandling i 12 uger efterfulgt af 40 uger uden behandling. 
In these 52 week duration studies, patients received treatment for 12 weeks, followed by a 40 week non-treatment phase.
Ubehag i brystet, influenzalignende symptomer, pyreksi, asteni, utilpashed 
Chest discomfort, influenza like illness, pyrexia, asthenia, malaise Feeling cold, cyst
- Betændelse i næse og hals, unormale drømme, søvnbesvær, hovedpine - Kvalme 
Very common: may affect more than 1 in 10 people o Inflammation of the nose and throat, abnormal dreams, difficulty sleeping, headache, o Nausea
CHAMPIX 0,5 mg filmovertrukne tabletter CHAMPIX 1 mg filmovertrukne tabletter 
NAME OF THE MEDICINAL PRODUCT CHAMPIX 0.5 mg film-coated tablets CHAMPIX 1 mg film-coated tablets
2,30 (1,83, 2,90), P<0,0001 2,00 (1,56, 2,55), P<0,0001 
2.30 (1.83, 2.90), P<0.0001
Abnorm levertest 
Liver function test abnormal
1,52 (1,23, 1,89), P=0,0001 1,51 (1,19, 1,93), P=0,0008 
1.52 (1.23, 1.89), P=0.0001
- Vedligeholdelsespakninger, der indeholder 2 eller 4 gennemsigtige blisterkort hver med 14 eller 2 gennemsigtige blisterkort med 28 x CHAMPIX 1 mg filmovertrukne tabletter i en kortpakning. 
Follow-on (maintenance) packs containing 2 or 4 clear blisters of 14 or 2 clear blisters of 28 x CHAMPIX 1 mg film-coated tablets in card packaging.
I dette studie, der forløb over 52 uger, fik patienterne behandling i 12 uger efterfulgt af en behandlingsfri opfølgningsperiode på 40 uger. 
In this 52-week duration study, patients received treatment for 12 weeks, followed by a 40-week non-treatment follow-up phase.
Et kardiovaskulært sikkerhedsvurderingsstudie, hvori der indgik 4595 af de 6293 forsøgspersoner, som gennemførte hovedstudiet (N=8058) og blev fulgt til og med uge 52. 
Cardiovascular safety assessment study in subjects with and without a history of psychiatric disorder The cardiovascular (CV) safety of CHAMPIX was evaluated in the Study in Subjects with and without a History of Psychiatric Disorder (parent study; see section 5.1 - Neuropsychiatric safety) and its nontreatment extension, the Cardiovascular Safety Assessment Study, which enrolled 4595 of the 6293 subjects who completed the parent study (N=8058) and followed them through week 52.
- Startpakning i en ydre carton, der indeholder 1 pakke med 1 gennemsigtig blisterkort med 11 x CHAMPIX 0,5 mg og 14 x 1 mg filmovertrukne tabletter og 1 gennemsigtigt blisterkort med 28 eller 2 gennemsigtige blisterkort med 14 x CHAMPIX 1 mg filmovertrukne tabletter i en kortpakning og 2 pakker, der hver indeholder 2 gennemsigtige blisterkort med 28 eller 4 gennemsigtige blisterkort med 14 x CHAMPIX 1 mg filmovertrukne tabletter i en kortpakning. 
Treatment initiation pack in an outer carton containing 1 pack with 1 clear blister of 11 x CHAMPIX 0.5 mg and 14 x 1 mg film-coated tablets and 1 clear blister of 28 or 2 clear blisters of 14 x CHAMPIX 1 mg film-coated tablets in card packaging and 2 packs each containing 2 clear blisters of 28 or 4 clear blisters of 14 x CHAMPIX 1 mg film-coated tablets in card packaging.
Under behandlingen Antal vurderet Suicidaladfærd og/eller -tanker Suicidaladfærd Suicidaltanker Under opfølgning Antal vurderet 
During treatment Number assessed Suicidal behaviour and/or ideation Suicidal behaviour Suicidal ideation
LÆGEMIDDELFORM OG INDHOLDS (PAKNINGSSTØRRELSE) 
PHARMACEUTICAL FORM AND CONTENTS
1,96 (1,51, 2,54), P<0,0001 1,5 (1,24, 2,20), P=0,0007 
1.96 (1.51, 2.54), P<0.0001
CHAMPIX 0,5 mg filmovertrukne tabletter 
NAME OF THE MEDICINAL PRODUCT CHAMPIX 0.5 mg film-coated tablets
KARTON TIL DELPAKNING 
Treatment initiation packs
2,99 (2,33, 3,83), P<0,0001 2,50 (1,90, 3,29), P<0,0001 
2.99 (2.33, 3.83), P<0.0001
4,00 (3,20, 5,00), P<0,0001 3,24 (2,56, 4,11), P<0,0001 
3.24 (2.56, 4.11), P<0.0001
1 varmeforseglet kortpakning indeholdende 11 x 0,5 mg og 14 x 1 mg vareniclin filmovertrukne tabletter og 1 blisterpakning med 28 eller 2 blisterpakninger med 14 x 1 mg vareniclin filmovertrukne tabletter og 2 varmeforseglede kortpakninger, hver indeholdende 2 blisterpakninger med 28 eller 4 blisterpakninger med 14 x 1 mg vareniclin filmovertrukne tabletter - indre og ydre mærkning. 
1 x heat sealed card pack containing 11 x 0.5 mg and 14 x 1 mg varenicline film-coated tablets and 1 blister pack of 28 or 2 blister packs of 14 x 1 mg varenicline film-coated tablets and 2 x heat sealed card packs each containing 2 blister packs of 28 or 4 blister packs of 14 x 1 mg varenicline film-coated tablets - outer and inner labelling.
Lidelser og forstyrrelser med nedtrykthed Affektive lidelser og forstyrrelser IKA* * IKA: ikke klassificeret andetsteds 
Anxiety disorders and symptoms Depressed mood disorders and disturbances Mood disorders and disturbances NEC*
1,77 (1,46, 2,14), P<0,0001 1,74 (1,41, 2,14), P<0,0001 
1.74 (1.41, 2.14), P<0.0001
Blisterpakning med 14 x 0,5 mg og 28 x 0,5 mg vareniclin filmovertrukne tabletter, varmeforseglet kortpakning 
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Blister pack of 14 x 0.5 mg and 28 x 0.5 mg varenicline film-coated tablets, heat sealed card
Kontakt lægen, før De tager CHAMPIX. 
You should ask your doctor or pharmacist for advice before taking CHAMPIX.
CHAMPIX 1 mg filmovertrukne tabletter 
NAME OF THE MEDICINAL PRODUCT CHAMPIX 1 mg film-coated tablets
Øre og labyrint Ikke almindelig 
Ear and labyrinth disorders
1,49 (1,20, 1,85), P=0,0003 1,41 (1,11, 1,79), P=0,0047 
1.41 (1.11, 1.79), P=0.0047
Forekomsten af hændelser for det sammensatte endepunkt var højere for hver af de aktive behandlinger sammenlignet med placebo, men brugen af vareniclin, bupropion og nikotinplaster i den psykiatriske kohorte var ikke forbundet med en signifikant øget risiko for NPS bivirkninger i det sammensatte primære endepunkt sammenlignet med placebo (95 % CI inkluderede nul). 
However, the use of varenicline, bupropion and NRT in the psychiatric cohort was not associated with a significantly increased risk of NPS adverse events in the composite primary endpoint compared with placebo (95% CIs included zero).
Øjne Ikke almindelig 
Eye disorders Uncommon Rare
Forhøjet blodtryk, hedestigninger 
Blood pressure increased, hot flush Respiratory, thoracic and mediastinal disorders
CHAMPIX 0,5 mg 
0.5 mg
- Betændelse i brystkassen, betændelse i bihuler - Vægtstigning, manglende appetit, øget appetit - Søvnighed, svimmelhed, ændret smagssans - Stakåndethed, hoste - Halsbrand, opkastning, forstoppelse, diarré, oppustethed, mavesmerter, tandpine, dårlig fordøjelse, luft i maven, tør mund - Udslæt, kløe - Ledsmerter, muskelsmerter, rygsmerter - Smerter i brystmusklerne, udmattethed 
Common: may affect up to 1 in 10 people o Chest infection, inflammation of the sinuses o Increased weight, decreased appetite, increased appetite o Sleepiness, dizziness, changes in the way things taste o Shortness of breath, cough o Heartburn, vomiting, constipation, diarrhoea, feeling bloated, abdominal pain, toothache,
N=1026 n (%) 
Varenicline N=1026 n (%)
Varmeforseglet kortpakning indeholdende 2 blisterpakninger med 28 eller 4 blisterpakninger med 14 x 1 mg vareniclin filmovertrukne tabletter - indre og ydre mærkning 
Heat sealed card pack containing 2 blister packs of 28 or 4 blister packs of 14 x 1 mg varenicline film-coated tablets- inner and outer labelling
PCTFE/PVC-blister med aluminiumsfolie, indeholdende 1 gennemsigtig blister med 11 x 0,5 mg og 14 x 1 mg filmovertrukne tabletter og 1 gennemsigtig blister med 28 eller 2 gennemsigtige blistere med 14 x 1 mg filmovertrukne tabletter i en sekundær varmeforseglet kortpakning og PCTFE/PVCblister med aluminiumsfolie i to sekundære varmeforseglede kortpakninger indeholdende 56 x 1 mg filmovertrukne tabletter. 
PCTFE/PVC blisters with aluminium foil backing containing one clear blister of 11 x 0.5 mg and 14 x 1 mg film-coated tablets and 1 clear blister of 28 or 2 clear blisters of 14 x 1 mg film-coated tablets in one secondary heat sealed card pack and PCTFE/PVC blisters with aluminium foil backing in two secondary heat sealed card packs each containing 56 x 1 mg film-coated tablets.
PVC-blister med aluminiumsfolie, indeholdende 112 x 1 mg filmovertrukne tabletter i en karton. 
PVC blisters with aluminium foil backing in a pack containing 112 x 1 mg film-coated tablets in a carton.
CA* uge 13-24 
CA* wk 15-24
N=990 n (%) 
Varenicline N=990 n (%)
Varmeforseglet kortpakning, indeholdende enten 2 eller 4 blisterpakninger hver med 14 x 0,5 mg vareniclin filmovertrukne tabletter eller 2 blisterpakninger hver med 28 x 0,5 mg vareniclin filmovertrukne tabletter - indre og ydre mærkning 
Heat sealed card pack containing either 2 or 4 blister packs of 14 x 0.5 mg varenicline film-coated tablets or 2 blister packs of 28 x 0.5 mg varenicline film-coated tablets- inner and outer labelling
En blisterpakning med 28 eller 2 blisterpakninger med 14 x 1 mg vareniclin filmovertrukne tabletter, varmeforseglet kortpakning 
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS One blister pack of 28 or 2 blister packs of 14 x 1 mg varenicline film-coated tablets, heat sealed card
Ledstivhed, costochondritis 
Silica, Colloidal Anhydrous
PCTFE/PVC-blister med aluminiumsfolie, indeholdende 112 x 1 mg filmovertrukne tabletter i en karton. 
PCTFE/PVC blisters with aluminium foil backing in a pack containing 112 x 1 mg film-coated tablets in a carton.
Varmeforseglet kortpakning, indeholdende 1 blisterpakning med 11 x 0,5 mg vareniclin filmovertrukne tabletter og 1 blisterpakning med 14 x 1 mg vareniclin filmovertrukne tabletter - indre og ydre mærkning 
Heat sealed card pack containing 1 blister pack of 11 x 0.5 mg varenicline film-coated tablets and 1 blister pack of 14 x 1 mg varenicline film-coated tablets - inner and outer labelling
- Startpakning, der indeholder 2 blisterkort; 1 gennemsigtig blisterkort med 11 x CHAMPIX 0,5 mg og 14 x 1 mg filmovertrukne tabletter og 1 gennemsigtigt blisterkort med 28 eller 2 gennemsigtige blisterkort med 14 x CHAMPIX 1 mg filmovertrukne tabletter i en kortpakning. 
Treatment initiation pack containing 2 blisters; 1 clear blister of 11 x CHAMPIX 0.5 mg and 14 x 1 mg film-coated tablets and 1 clear blister of 28 or 2 clear blisters of 14 x CHAMPIX 1 mg film-coated tablets in card packaging.
- Startpakning, der indeholder 2 blisterkort; 1 gennemsigtigt blisterkort med 11 x CHAMPIX 0,5 mg filmovertrukne tabletter og 1 gennemsigtigt blisterkort med 14 x CHAMPIX 1 mg filmovertrukne tabletter i en karton. 
Treatment initiation pack containing 2 blisters; 1 clear blister of 11 x CHAMPIX 0.5 mg film-coated tablets and 1 clear blister of 14 x CHAMPIX 1 mg film-coated tablets in a carton.
PVC-blister med aluminiumsfolie, indeholdende 56 x 1 mg filmovertrukne tabletter i en karton. 
PVC blisters with aluminium foil backing in a pack containing 56 x 1 mg film-coated tablets in a carton.
Hver filmovertrukken tablet indeholder 1 mg vareniclin (som tartrat). 
Each 1 mg film-coated tablet contains 1 mg of varenicline (as tartrate).
PVC-blister med aluminiumsfolie, indeholdende 1 gennemsigtig blister med 11 x 0,5 mg og 14 x 1 mg filmovertrukne tabletter og 1 gennemsigtig blister med 28 meller 2 gennemsigtige blistere med 14 x 1 mg filmovertrukne tabletter i en sekundær varmeforseglet kortpakning og PVC-blister med aluminiumsfolie i to sekundære varmeforseglede kortpakninger indeholdende 56 x 1 mg filmovertrukne tabletter. 
PVC blisters with aluminium foil backing containing one clear blister of 11 x 0.5 mg and 14 x 1 mg film-coated tablets and 1 clear blister of 28 or 2 clear blisters of 14 x 1 mg film-coated tablets in one secondary heat sealed card pack and PVC blisters with aluminium foil backing in two secondary heat sealed card packs each containing 56 x 1 mg film-coated tablets.
PVC-blister med aluminiumsfolie, indeholdende 140 x 1 mg filmovertrukne tabletter i en karton. 
PVC blisters with aluminium foil backing in a pack containing 140 x 1 mg film-coated tablets in a carton.
PCTFE/PVC-blister med aluminiumsfolie, indeholdende 56 x 1 mg filmovertrukne tabletter i en karton. 
PCTFE/PVC blisters with aluminium foil backing in a pack containing 56 x 1 mg film-coated tablets in a carton.
PVC-blister med aluminiumsfolie, indeholdende 28 x 1 mg filmovertrukne tabletter i en karton. 
PVC blisters with aluminium foil backing in a pack containing 28 x 1 mg film-coated tablets in a carton.
Bupropion kontra placebo 2,26 (1,80, 2,85), P<0,0001 1,87 (1,46, 2,39), P<0,0001 NRT vs placebo 
Varenicline vs Bupropion 1.49 (1.20, 1.85), P=0.0003
Startpakninger: EU/1/06/360/003 EU/1/06/360/008 EU/1/06/360/012 EU/1/06/360/014 EU/1/06/360/019 EU/1/06/360/023 EU/1/06/360/025 EU/1/06/360/026 
EU/1/06/360/003 EU/1/06/360/008 EU/1/06/360/012 EU/1/06/360/014 EU/1/06/360/019 EU/1/06/360/023 EU/1/06/360/025 EU/1/06/360/026
PCTFE/PVC-blister med aluminiumsfolie, indeholdende 28 x 1 mg filmovertrukne tabletter i en sekundær varmeforseglet kortpakning. 
PCTFE/PVC blisters with aluminium foil backing in a pack containing 28 x 1 mg film-coated tablets in secondary heat sealed card packaging.
Blisterpakning med 14 x 1 mg og 28 x 1 mg vareniclin filmovertrukne tabletter, varmeforseglet kortpakning 
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Blister pack of 14 x 1 mg and 28 x 1 mg varenicline film-coated tablets, heat sealed card
PCTFE/PVC-blister med aluminiumsfolie, indeholdende 28 x 0,5 mg filmovertrukne tabletter i en sekundær varmeforseglet kortpakning. 
PCTFE/PVC blisters with aluminium foil backing in a pack containing 28 x 0.5 mg film-coated tablets in secondary heat sealed card packaging.
PCTFE/PVC-blister med aluminiumsfolie, indeholdende 140 x 1 mg filmovertrukne tabletter i en karton. 
PCTFE/PVC blisters with aluminium foil backing in a pack containing 140 x 1 mg film-coated tablets in a carton.
Varmeforseglet kortpakning, indeholdende enten 2 eller 4 blisterpakninger hver med 14 x 1 mg vareniclin filmovertrukne tabletter eller 2 blisterpakninger hver med 28 x 1 mg vareniclin filmovertrukne tabletter - indre og ydre mærkning 
Heat sealed card pack containing either 2 or 4 blister packs of 14 x 1 mg varenicline film-coated tablets or 2 blister packs of 28 x 1 mg varenicline film-coated tablets- inner and outer labelling
PCTFE/PVC-blister med aluminiumsfolie, indeholdende 56 x 1 mg filmovertrukne tabletter i en sekundær varmeforseglet kortpakning. 
PCTFE/PVC blisters with aluminium foil backing in a pack containing 56 x 1 mg film-coated tablets in secondary heat sealed card packaging.
PCTFE/PVC-blister med aluminiumsfolie, indeholdende 56 x 0,5 mg filmovertrukne tabletter i en sekundær varmeforseglet kortpakning. 
PCTFE/PVC blisters with aluminium foil backing in a pack containing 56 x 0.5 mg film-coated tablets in secondary heat sealed card packaging.
PVC-blister med aluminiumsfolie, indeholdende 28 x 1 mg filmovertrukne tabletter i en sekundær varmeforseglet kortpakning. 
PVC blisters with aluminium foil backing in a pack containing 28 x 1 mg film-coated tablets in secondary heat sealed card packaging.
PVC-blister med aluminiumsfolie, indeholdende 56 x 1 mg filmovertrukne tabletter i en sekundær varmeforseglet kortpakning. 
PVC blisters with aluminium foil backing in a pack containing 56 x 1 mg film-coated tablets in secondary heat sealed card packaging.
PCTFE/PVC-blister med aluminiumsfolie, indeholdende 28 x 1 mg filmovertrukne tabletter i en karton. 
PCTFE/PVC blisters with aluminium foil backing in a pack containing 28 x 1 mg film-coated tablets in a carton.
PVC-blister med aluminiumsfolie, indeholdende 28 x 0,5 mg filmovertrukne tabletter i en sekundær varmeforseglet kortpakning. 
PVC blisters with aluminium foil backing in a pack containing 28 x 0.5 mg film-coated tablets in secondary heat sealed card packaging.
PVC-blister med aluminiumsfolie, indeholdende 56 x 0,5 mg filmovertrukne tabletter i en sekundær varmeforseglet kortpakning. 
PVC blisters with aluminium foil backing in a pack containing 56 x 0.5 mg film-coated tablets in secondary heat sealed card packaging.
Resultaterne viste samme incidens af kombinerede neuropsykiatriske bivirkninger - bortset fra søvnlidelser - hos patienter, der blev behandlet med vareniclin, sammenlignet med de patienter, der fik placebo. 
The results showed a similar incidence of combined neuropsychiatric adverse events, other than sleep disorders, in patients treated with varenicline compared to patients treated with placebo, with a risk ratio (RR) of 1.01 (95% CI: 0.89-1.15).
2,00 (1,54, 2,59), P<0,0001 1,77 (1,33, 2,36), P<0,0001 
2.00 (1.54, 2.59), P<0.0001
Konjunktivitis, øjensmerter 
Conjunctivitis, eye pain
PVC-blister med aluminiumsfolie, indeholdende 1 gennemsigtig blister med 11 x 0,5 mg og 14 x 1 mg filmovertrukne tabletter og 1 gennemsigtig blister med 28 eller 2 gennemsigtige blistere med 14 x 1 mg filmovertrukne tabletter i en sekundær varmeforseglet kortpakning. 
PVC blisters with aluminium foil backing containing 1 clear blister of 11 x 0.5 mg and 14 x 1 mg film-coated tablets and 1 clear blister of 28 or 2 clear blisters of 14 x 1 mg film-coated tablets in secondary heat sealed card packaging.
PCTFE/PVC-blister med aluminiumsfolie, indeholdende 1 gennemsigtig blister med 11 x 0,5 mg filmovertrukne tabletter og 1 gennemsigtig blister med 14 x 1 mg filmovertrukne tabletter i en karton. 
PCTFE/PVC blisters with aluminium foil backing containing 1 clear blister of 11 x 0.5 mg film-coated tablets and a second clear blister containing 14 x 1 mg film-coated tablets in a carton.
Føler sig unormal Fjendtlighed 
Feeling abnormala Hostilitya Agitationb Aggression b